Home・Elenco Azioni・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Aperta

SettoreSettore sanitario

6.42 0.16

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.3

Massimo

6.48

Metriche Chiave
By Trading Economics
Entrata	36M -3.7M
Vendite	16M 66M
EPS	0.01
Margine di Profitto	-5.67
Dipendenti	416
EBITDA	54M 12M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	-11.68% downside

Dividendi
By Acuity
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.1B 2.5B
Apertura precedente	6.26
Chiusura precedente	6.42

Notizie sul Sentiment di mercato

By Acuity

100%

320 / 340 Classifica in Healthcare

Maravai LifeSciences Holdings Inc (Class A) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 19:46 UTC

Maravai LifeSciences Holdings Inc shares are lower during Monday's session, trading below their 20-day moving average with no specific news to explain the decline.

31 lug 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc. shares are lower today amid broader market volatility, having previously dropped to a session low before partially recovering.

30 lug 2026, 16:56 UTC

Maravai LifeSciences Holdings Inc shares are gaining amid broader market recovery, with the S&P 500 advancing as investors engage in bargain hunting.

29 lug 2026, 20:09 UTC

Maravai LifeSciences Holdings Inc shares declined during Wednesday's session, pulling back from earlier gains amid broader market volatility and rising oil prices.

28 lug 2026, 18:06 UTC

Maravai LifeSciences Holdings Inc is gaining during Tuesday's session, though it pulled back from earlier highs amid broader market pressure in the tech sector.

24 lug 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market pressures, reflecting declines in the Nasdaq 100 following disappointing earnings from major tech companies.

23 lug 2026, 09:01 UTC

Maravai LifeSciences Holdings Inc. shares are lower in pre-market trading, continuing a decline since Wednesday's close without significant recovery.

22 lug 2026, 19:56 UTC

Maravai LifeSciences Holdings Inc. shares are lower today, retracing from earlier highs amid no specific company news. The stock remains above its 20-day moving average.

21 lug 2026, 19:56 UTC

News

Maravai LifeSciences' TriLink BioTechnologies secures a patent for CleanCap® technology in China, boosting confidence in RNA-based therapies. Shares are higher since Monday's close.

20 lug 2026, 20:02 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market declines. The stock hit a session low earlier but has since recovered slightly.

Confronto tra pari

Modifica del prezzo

Maravai LifeSciences Holdings Inc (Class A) Previsione

Obiettivo di Prezzo

By TipRanks

-11.68% in calo

Previsioni per 12 mesi

Media 5.67 USD -11.68%

Alto 6 USD

Basso 5 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Maravai LifeSciences Holdings Inc (Class A) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Maravai LifeSciences Holdings Inc (Class A) - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

320 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.